Kairos Pharma Reports Positive Interim Data for ENV105 in Prostate Cancer Trial
TL;DR
Kairos Pharma's ENV105 combination therapy offers investors a competitive edge with median progression-free survival exceeding 13 months versus standard 3.7 months in prostate cancer.
ENV105 targets CD105 protein to reverse drug resistance, combining with apalutamide to achieve PSA declines in 7 of 9 patients with no dose-limiting toxicities observed.
This breakthrough therapy extends survival for metastatic prostate cancer patients, reducing treatment resistance and improving quality of life for those facing limited options.
Kairos Pharma's antibody therapy defies cancer drug resistance, showing remarkable 13+ month survival in patients who previously had only 3.7 months expected.
Found this article helpful?
Share it with your network and spread the knowledge!
Kairos Pharma Ltd. has reported positive interim efficacy data from its ongoing Phase 2 trial of ENV105 in metastatic castration-resistant prostate cancer. The combination treatment of ENV105 and apalutamide achieved median progression-free survival exceeding 13 months among eight evaluable patients, with five patients remaining on treatment and seven of nine showing declines in prostate-specific antigen levels. These results significantly surpassed the trial's target of a 45% improvement compared to the standard 3.7 months progression-free survival typically seen with second- or third-line hormone therapy.
The treatment demonstrated favorable tolerability with no dose-limiting toxicities observed during the study period. ENV105 represents a novel approach to cancer treatment as an antibody targeting CD105, a protein identified as a key driver of resistance to various cancer therapies. The elevation of CD105 in response to standard treatments often leads to resistance and disease relapse, making ENV105's mechanism of targeting this protein particularly significant for overcoming treatment barriers. The full press release detailing these findings can be accessed at https://ibn.fm/BSLuY.
The positive interim data suggest that ENV105 may effectively reverse drug resistance and restore the effectiveness of standard therapies across multiple cancer types. Currently, ENV105 is also undergoing a Phase 1 clinical trial for lung cancer, addressing significant unmet medical needs in oncology. The treatment's ability to extend progression-free survival beyond established benchmarks indicates potential for improving outcomes for patients with advanced prostate cancer who have limited treatment options.
These findings come at a critical time when new approaches are needed to combat treatment resistance in advanced cancers. The combination therapy's performance in this Phase 2 trial positions ENV105 as a promising candidate for addressing the challenges of metastatic castration-resistant prostate cancer, potentially offering new hope for patients facing this aggressive disease form. Additional information about the company's developments is available in their newsroom at https://ibn.fm/KAPA.
Curated from InvestorBrandNetwork (IBN)
